JP Morgan Chase’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.69M Buy
362,501
+18,888
+5% +$573K ﹤0.01% 2933
2026
Q1
$9.54M Sell
343,613
-25,521
-7% -$680K ﹤0.01% 2722
2025
Q4
$10.7M Buy
369,134
+179,335
+94% +$2.34M ﹤0.01% 2617
2025
Q3
$1.37M Sell
189,799
-5,390
-3% -$39.7K ﹤0.01% 4358
2025
Q2
$1.94M Buy
195,189
+177,764
+1,020% +$1.88M ﹤0.01% 3947
2025
Q1
$165K Buy
17,425
+745
+4% +$10.3K ﹤0.01% 5328
2024
Q4
$230K Sell
16,680
-39,519
-70% -$692K ﹤0.01% 5419
2024
Q3
$855K Buy
56,199
+45,381
+419% +$224K ﹤0.01% 4568
2024
Q2
$51.6K Sell
10,818
-80,265
-88% -$448K ﹤0.01% 5848
2024
Q1
$618K Buy
+91,083
New +$440K ﹤0.01% 4654
2021
Q3
Sell
-77
Closed 6495
2021
Q2
$0 Buy
+77
New +$326 ﹤0.01% 6360
2020
Q4
Sell
-5,607
Closed -$30K 5645
2020
Q3
$30K Buy
5,607
+5,600
+80,000% +$32.6K ﹤0.01% 5072
2020
Q2
$0 Buy
+7
New +$31 ﹤0.01% 5391
2017
Q4
Sell
-200
Closed -$4K 5437
2017
Q3
$4K Hold
200
﹤0.01% 4807
2017
Q2
$2K Buy
+200
New +$3.66K ﹤0.01% 4839

Other funds holding CAPR

JP Morgan Chase's CAPR Position: Q2 2026 in Review

JP Morgan Chase increased its Capricor Therapeutics (CAPR) stake by 5.5% in Q2 2026, buying an estimated $573K and bringing the position to 362,501 shares worth $8.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2933.

JP Morgan Chase first reported a position in CAPR in Q2 2017 and has held it in 15 quarters since. The position peaked at $10.7M in Q4 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • JP Morgan Chase held 362,501 shares of Capricor Therapeutics worth $8.69M as of Q2 2026.
  • JP Morgan Chase bought 18,888 Capricor Therapeutics shares in Q2 2026, an estimated $573K.
  • Capricor Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2933 holding.
  • JP Morgan Chase first reported a position in Capricor Therapeutics in Q2 2017 and has held it in 15 quarters since.
  • JP Morgan Chase's Capricor Therapeutics position peaked at $10.7M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.